Skip to main content
Article thumbnail
Location of Repository

Concordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent

By Michela Frendo, John Paul Caruana Galizia and Andrew A. Borg


Aims: The aim of this study is to assess concordance with the British Society of Rheumatology (BSR) 2010 recommendations on the use of biologic therapy in Rheumatoid Arthritis (RA). The Disease Activity Score in 28 joints (DAS 28), a composite numerical score is included in these recommendations to assess disease activity and response to treatment. \ud Methods: Clinical notes of fifty patients who were commenced on biologic treatment between March 2010 and June 2011 were reviewed for documentation of DAS 28 scores at baseline, after approximately 6 months of commencement of treatment and at approximately 6 monthly intervals during treatment. \ud Results: Twenty two patients were eligible for this audit. Of these patients only half had a DAS 28 score performed prior to starting treatment, four patients had the score performed within 3-9 months of commencement of therapy and only 2 patients had continuous scores performed at six monthly intervals during treatment. \ud Conclusions: This audit shows that we are not adhering to the BSR recommendations. In order to improve our adherence we plan to train all staff in contact with patients on biologic treatment to perform DAS 28 scores and have a DAS 28 calculator readily available at out patients. A proforma is being developed for patients on biologic therapy to ensure that DAS 28 scores are performed at baseline and during treatment

Topics: Rheumatoid arthritis -- Treatment, Antirheumatic agents, Rheumatoid arthritis -- Treatment -- Medical audit
Publisher: Malta Medical Journal
Year: 2013
OAI identifier:
Provided by: OAR@UM

Suggested articles


  1. (2001). Anti – TNF therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol doi
  2. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatol doi
  3. New therapies for treatment of rheumatoid arthritis. doi
  4. Regular review of patients on biologic therapies to identify patients who have an inadequate response to biologics according to BSR and EULAR criteria. In these patients switching of a
  5. Training of all staff in the Department caring for patients on biologics to standardize performance of the DAS 28 and consequently minimize interand intra- observer variation.
  6. Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents: A Cost-Effectiveness Analysis. doi
  7. (2005). van Riel PL The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.